For the past couple weeks I've been writing on this blog and in our newsletter about FDA drug approval dates (PDUFA dates) and the impact that these catalysts can have on a drug manufacturer's stock price. This week I thought I would let our partner Informa do most of the talking. And why not, considering their opinions successfully predicted 75% of the catalyst outcomes that occurred in Q4 2015!
Click HERE for Informa's Early 2016 Outlook Report that highlights the impact of several significant catalyst events from Q4 2015 and includes details and opinions on twenty-two (22) upcoming drug and device/diagnostic events expected to occur in early 2016. In addition, there is an extensive listing of large impact catalysts in the drug and device/diagnostic areas through early 2016. Enjoy!
Recent Content
-
_thumb.png)
CEO Uncertainty Spikes After Improving Last Quarter
-
_thumb.png)
Earnings Season Heats Up, Spotting Two Unusual Reporting Dates in the Consumer Space
-
Data Minds - Triple Threat: Leveraging Data to Manage AI, ESG, and ETF Risks | April 11, 2024 [Recording Available]
-
Seeking Alpha: Q1 2024 Earnings Preview: Will Reports Be Good Enough To Turn Markets Positive
-
_thumb.png)
Q1 2024 Earnings Preview: Will Reports be Good Enough to Turn Markets Positive?
-
[Podcast] Interactive Brokers: The Ins and Outs of Earnings Announcements
-
Pensions & Investments: U.S. companies increase buyback announcements
-
_thumb.png)
Shareholder Meetings in Focus as Earnings Season Begins
-
Investing.com: Volatility Ahead: How Shareholder Meetings Could Shake Up Your Portfolio
-
_thumb.png)
Q2 2024 Investor Conference & Events Highlights
